Journal
ARCHIVES OF VIROLOGY
Volume 166, Issue 3, Pages 949-954Publisher
SPRINGER WIEN
DOI: 10.1007/s00705-021-04956-9
Keywords
-
Categories
Ask authors/readers for more resources
Favipiravir shows promising efficacy in the treatment of COVID-19, reducing hospital stay and the need for mechanical ventilation.
No specific antiviral drugs have been approved for the treatment of COVID-19. This study aimed to evaluate the efficacy of favipiravir in treatment of COVID-19. This was a multicenter randomized controlled study including 96 patients with COVID- 19 who were randomly assigned into a chloroquine (CQ) group and a favipiravir group. None of the patients in the favipiravir group needed mechanical ventilation (p = 0.129). One patient (2.3%) in the favipiravir group and two patients (4.2%) in the CQ group died (p = 1.00). Favipiravir is a promising drug for COVID-19 that decreases the hospital stay and the need for mechanical ventilation. ClinicalTrials.gov Identifier NCT04351295.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available